27 January 2022

Download as PDF

tranScrip is delighted to announce the appointment of Dr Jon Sisson as a Senior Partner.Dr Jon Sisson

Jon is a pharmaceutical physician with extensive knowledge of medicines development and regulation across the whole product lifecycle.

Before moving to tranScrip, Jon was a medical assessor at the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for over 20 years. Initially, Jon worked in the post-licensing division across all therapeutic areas, with a focus on license variations, safety reviews and advertising issues. After 10 years in post-licensing, he moved to the licensing division, to assess  new license applications (new chemical entities and generics) and provide national scientific advice to companies. This mainly covered products for cardiovascular conditions and diabetes, but Jon has gained cumulative experience in a wider range of therapy areas, particularly when serving as a UK representative on the Committee for Medicinal Products for Human Use (CHMP) Scientific Advice Working Party. 

Previously, following clinical training in internal medicine, Jon worked in the Hoechst and GlaxoWellcome clinical pharmacology units, including as Principal Investigator in first-in-man studies. 

Jon has a particular interest in clinical pharmacology and pharmacokinetics, bioequivalence studies and structured benefit:risk assessment. He is a member of the Faculty of Pharmaceutical Medicine’s Board of Examiners and is the convenor for the MCQ section for the DipPharmMed exam.

Marcin Mankowski, tranScrip’s Managing Partner said, “We are delighted to welcome Jon to our team. His expertise in clinical pharmacology and pharmaceutical development combined with in-depth understanding of regulatory pathways and requirements for drug approval will bring a lot of value to our clients’ clinical programmes.”